Experts to scrutinize licensure paths for 1st Ebola vaccines
This article was originally published in Scrip
Executive Summary
At a 12 May meeting, the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) is expected to mull over the conundrum of how to license Ebola vaccines when there's likely not going to be enough study participants to provide adequate results in the ongoing randomized controlled trials.